Illuccix® Receives European Approval - Telix Pharmaceuticals (NASDAQ:TLX)

Illuccix® Receives European Approval - Telix Pharmaceuticals (NASDAQ:TLX)

MELBOURNE, Australia and LIÈGE, Belgium, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces that it has received a positive decision on the Marketing Authorization Application (MAA) for its prostate cancer PET1 imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection), which was submitted in Europe via a decentralized procedure (DCP). This signific…

Illuccix approved in Europe for detection of PSMA-positive lesions

The European approval of Illuccix adds on to prior approvals in the US, Australia, and Canada.

Surging Stocks: What’s Fueling Telix Pharmaceuticals’ Skyrocketing Shares?

Telix Pharmaceuticals Sees Record Gains on Exciting News Telix Pharmaceuticals Ltd (ASX: TLX) has witnessed a remarkable surge, with shares climbing 4.5% to a historic peak of $27.00. Investors have shown enthusiasm following an announcement about the company’s innovative product, Illuccix, designed for prostate cancer diagnostics. The Illuccix agent is a radioactive diagnostic tool, prepared by healthcare professionals and used in conjunction w…

Illuccix® Receives European Approval

Melbourne (Australia) and Liège (Belgium) | 17 January 2025 Telix today announces that it has received a positive decision on the Marketing Authorization Application (MAA) for its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection), which was submitted in Europe via a decentralized procedure (DCP). This significant milestone follows the issuance of the Final Assessment Report from the Ger…